DPP-4 inhibitors suppress cytokine production [14], inhibit monocyte infiltration to tissue niches [36], reduce the disease severity of rheumatoid arthritis in an animal model [16], suppress the inflammatory response in association with multiple sclerosis [47], and suppress the symptoms of inflammatory bowel disease [48]. This evidence concerns the gene DPP4 and rheumatoid arthritis.